Literature DB >> 25170587

International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation.

Winnie W Nelson1, Sunita Desai, C V Damaraju, Lang Lu, Larry E Fields, Peter Wildgoose, Jeff R Schein.   

Abstract

BACKGROUND: Warfarin is effective for stroke prevention in patients with atrial fibrillation (AF), but international normalized ratio (INR) levels fluctuate and frequent monitoring is necessary.
METHODS: This study used data from a large anticoagulation management service database to analyze the relationship between INR stabilization and warfarin utilization for >1 year in patients with nonvalvular AF (NVAF). Anticoagulation records from a large US electronic database collected from 2006 to 2010 were analyzed.
RESULTS: Patients with NVAF and ≥ 3 INR values in the dataset were identified (n = 15,276). INR stabilization was defined as the first three consecutive INR values between 2.0 and 3.0 after warfarin initiation. One quarter of patients (n = 3809) failed to reach INR stabilization. After initial stabilization, 30% of subsequent INR values were out of range. The mean (± standard deviation [SD]) follow-up time from stabilization to the end of study for these patients was 494.2 ± 418.1 days. Age ≥ 75 years (odds ratio [OR] = 1.17, 95% confidence interval [CI] = 1.08-1.27), hypertension (OR = 1.19, 95% CI = 1.10-1.29), or prior stroke (OR = 1.29, 95% CI = 1.04-1.61) were positively associated with achieving stabilization; heart failure was negatively associated with stabilization (OR = 0.78, 95% CI = 0.70-0.87). Male gender (p < 0.0001) and hypertension were associated with earlier stabilization (p = 0.0013); heart failure was associated with later stabilization (p = 0.0098). Patients who achieved INR stabilization within 1 year were 10 times more likely to remain on warfarin than patients who did not achieve it. LIMITATIONS: Observational data may contain incomplete records. Data on adherence, concurrent medications, vitamin K intake, genotype, reasons for discontinuation of monitoring, and patient outcomes were not available in the dataset. The study findings were generalizable only to patients with AF who were managed by anticoagulation clinics.
CONCLUSION: Given the importance of stroke prevention among patients with AF, the potential for unpredictable INR patterns should be carefully considered during clinical decision-making.

Entities:  

Keywords:  International normalized ratio; Nonvalvular atrial fibrillation; Stabilization; Warfarin

Mesh:

Substances:

Year:  2014        PMID: 25170587     DOI: 10.1185/03007995.2014.957822

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  5 in total

1.  Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial).

Authors:  Tetz C Lee; Min Qian; Gregory Y H Lip; Marco R Di Tullio; Susan Graham; Douglas L Mann; Koki Nakanishi; John R Teerlink; Ronald S Freudenberger; Ralph L Sacco; J P Mohr; Arthur J Labovitz; Piotr Ponikowski; Dirk J Lok; Conrado Estol; Stefan D Anker; Patrick M Pullicino; Richard Buchsbaum; Bruce Levin; John L P Thompson; Shunichi Homma; Siqin Ye
Journal:  Am J Cardiol       Date:  2018-06-04       Impact factor: 2.778

2.  Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation.

Authors:  Lindsay G S Bengtson; Pamela L Lutsey; Lin Y Chen; Richard F MacLehose; Alvaro Alonso
Journal:  J Cardiol       Date:  2016-11-23       Impact factor: 3.159

3.  International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillation.

Authors:  Winnie W Nelson; Sunita Desai; Chandrasekharrao V Damaraju; Lang Lu; Larry E Fields; Peter Wildgoose; Jeffery R Schein
Journal:  Am J Cardiovasc Drugs       Date:  2015-06       Impact factor: 3.571

Review 4.  Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences.

Authors:  Jeff R Schein; C Michael White; Winnie W Nelson; Jeffrey Kluger; Elizabeth S Mearns; Craig I Coleman
Journal:  Thromb J       Date:  2016-06-13

5.  Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.

Authors:  Faye L Norby; Lindsay G S Bengtson; Pamela L Lutsey; Lin Y Chen; Richard F MacLehose; Alanna M Chamberlain; Ian Rapson; Alvaro Alonso
Journal:  BMC Cardiovasc Disord       Date:  2017-09-06       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.